Navigation Links
Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component
Date:4/13/2008

SAN DIEGO, April 13 /PRNewswire-USNewswire/ -- The Barbara Ann Karmanos Cancer Institute researchers today presented, at the American Association for Cancer Research annual meeting in San Diego, CA, the potential benefits of Thymoquinone (TQ), a compound present in the oil of black seeds (Nigella sativa), in treating pancreatic cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELOGO )

For centuries, these black seeds have been consumed in Asia, Africa and the Middle East to promote health and fight disease. TQ, an active component of the seeds, has been isolated for its promise as a chemopreventative agent. Pancreatic cancer cells currently have a high degree of inherent and acquired chemoresistance to standard chemotherapy agents Gemcitabine and/or Oxaliplatin, making these drugs only moderately effective.

"Our goal with this study was to increase the effectiveness of current pancreatic cancer treatments with a naturally occurring substance," said Sanjeev Banerjee, Ph.D., researcher, working under the leadership of Fazlul Sarkar, Ph.D., professor of pathology at the Karmanos Cancer Institute, Wayne State University. "We also explored the molecular mechanisms associated with TQ to promote better therapeutic outcomes."

Drs. Banerjee and Sarkar, along with Karmanos researchers Ramzi Mohammad, Ph.D. and Zhiwei Wang, Ph.D., pre-treated pancreatic tumor cells possessing different molecular signatures (HPAC, BxPC-3, Panc-1 and MDA Panc-28, COLO 357, L3.6pl), with TQ prior to administering Gemcitabine and Oxaliplatin. They found that TQ significantly enhanced the chemosensitivity of the tumor cells, making the Gemcitabine and Oxaliplatin agents more effective in treating the cancer. The TQ pre-treatment improved the drugs' effect on promoting cancer cell death and halting tumor cell growth.

Karmanos researchers also discovered at a molecular level, TQ down regulated the normally active NF-B transcription factor and several of its downstream effector genes responsible for metastasis and cell invasion. NF-B is involved in cellular responses to stimuli such as stress, free radicals, ultraviolet irradiation and bacterial or viral antigens. It also plays a key role in regulating the immune response to infection, and is instrumental in the development of many chronic diseases, including cancer. These results suggest that an important molecular target could be down regulated by TQ in reversing chemoresistance, as well as the inhibition of invasion and metastasis of pancreatic cancer.

Further research is currently underway at Karmanos to obtain better clues for TQ's efficacy in future Phase I/II clinical trials. Thus, the research team at Karmanos is actively collaborating with physicians both at the Karmanos Cancer Center and the MD Anderson Cancer Center in Houston, Texas for assessing the clinical utility of TQ.

About the Barbara Ann Karmanos Cancer Institute

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 39 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. John C. Ruckdeschel, M.D., is the Institute's president and chief executive officer. For more information call 1-800-KARMANOS or go to http://www.karmanos.org.

American Association for Cancer Research

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field.


'/>"/>
SOURCE Karmanos Cancer Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. McCarty Cancer Foundation Awards $50,000 Grant for Myeloma Research Program at Karmanos Cancer Institute
2. Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27
3. Kroger Pink Tag Campaign Raises $137,500 for Breast Cancer Research and Awareness at Karmanos Cancer Institute
4. Danialle Karmanos Work It Out Launches Dynamic Blog
5. Karmanos Cancer Center Most Preferred Hospital for Cancer Care According to 2007 Survey
6. Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality
7. Susan G. Komen for the Cure, Karmanos Cancer Institute, Community Leaders, Breast Cancer Survivors and Activists to Gather at Forum and Call for Action on Breast Cancer
8. Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
9. Researchers find disparities in depression among older Hispanics in US
10. Researchers Identify New Genetic Links to Psoriasis
11. Penn researchers discover modus operandi of heart muscle protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology: